Journey Medical (DERM) Receivables - Net (2020 - 2026)

Journey Medical's Receivables - Net history runs 7 years deep, the most recent figure standing at $25.0 million for Q1 2026.

• Quarterly Receivables - Net rose 38.65% year-over-year to $25.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.0 million (up 38.65% YoY) and the FY2025 annual result came in at $29.8 million, up 191.11% from the prior year.
• Receivables - Net was $25.0 million for Q1 2026 at Journey Medical, down from $29.8 million in the prior quarter.
• Across five years, Receivables - Net topped out at $31.2 million in Q1 2022 and bottomed at $8.0 million in Q3 2023.
• A 5-year average of $19.5 million and a median of $18.0 million in 2025 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2023 — Receivables - Net tumbled 72.0% — and 2025, when it surged 191.11%.
• Journey Medical's Receivables - Net stood at $28.2 million in 2022, then sank by 46.04% to $15.2 million in 2023, then sank by 32.79% to $10.2 million in 2024, then jumped by 191.11% to $29.8 million in 2025, then dropped by 16.09% to $25.0 million in 2026.
• Business Quant data shows DERM's Receivables - Net at $25.0 million in Q1 2026, $29.8 million in Q4 2025, and $18.0 million in Q3 2025.